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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a devastating condition characterized by progressive lung function
decline and early mortality. While early accurate diagnosis is essential for IPF treatment, data evaluating the impact of hospital
academic status on IPF-related mortality remains limited. Here we examined in-hospital mortality trends for patients with IPF
from 2013 to 2017. We hypothesized that in-hospital IPF mortality would be influenced by hospital academic setting.
Methods: Hospitalization data was extracted from the National Inpatient Sample (NIS) for subjects with an international
classification of disease code for IPF. In-hospital mortality stratified by hospital setting (academic versus non-academic) was the
primary outcome of interest, with secondary analyses performed for subgroups with and without respiratory failure and
requiring mechanical ventilation. Predictors of mortality were then assessed.
Results: Among 93,680 patients with IPF requiring hospitalization, 58,450 (62.4%) were admitted to academic institutions. In-
hospital mortality decreased significantly in those admitted to an academic hospital (p < 0.001) but remained unchanged in
patients admitted to a non-academic hospital. A plateau in-hospital mortality was observed among all hospitalized patients
(p = 0.12), with a significant decrease observed for patients with admitted respiratory failure (p < 0.001) and those placed on
mechanic ventilation (p < 0.001).
Conclusion: In-hospital mortality decreased significantly for patients with IPF admitted to an academic hospital, suggesting
that management strategies may differ by hospital setting. Mortality among those with respiratory failure and those requiring
mechanical ventilation has dropped significantly. Our findings may underscore the importance of promoting early referral to
an academic institution and adherence to international treatment guidelines.
Keywords: Idiopathic pulmonary fibrosis, Mortality, Academic hospital, Respiratory failure, Mechanical ventilation
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: alqalyoobis19@ecu.edu
1Division of Pulmonary, Critical Care and Sleep Medicine, Department of
Medicine, East Carolina University-Brody School of Medicine, Greenville,
North Carolina, USA
2Present address: Internal Medicine - Pulmonary, Critical Care, and Sleep
Medicine, Brody School of Medicine, Mail Stop 628, 3E-149, Greenville, NC
27834, USA
Full list of author information is available at the end of the article
Alqalyoobi et al. BMC Pulmonary Medicine          (2020) 20:289 
https://doi.org/10.1186/s12890-020-01328-y
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal
lung disease characterized by high mortality and unpre-
dictable natural history [1]. An uncommon, but deadly
complication of IPF is acute exacerbation, which often
results in respiratory failure (RF) and requires
hospitalization [2]. While acute exacerbations of IPF are
difficult to characterize due to lack of an international
classification of disease (ICD) code, IPF related hospitali-
zations have been suggested as a clinically meaningful
endpoint [2–6]. This is supported by prior work showing
respiratory hospitalization is associated with increased
short-term mortality risk in patients with IPF [7]. Thera-
peutic advances over the last decade have led to the first
FDA approved therapies for the treatment of IPF [8].
Anti-fibrotic therapies nintedanib and pirfenidone have
both been shown to slow lung function decline in pa-
tients with IPF [4, 9] and recent analyses suggest they
may improve survival, [10–12] reduce hospitalization, [4,
10] and exacerbation risk [4, 13].
While early accurate diagnosis is essential for IPF treat-
ment, significant disagreements between community-
based physicians and academic-based physicians in the
diagnosis of interstitial lung diseases have been described
before [14]. Besides, delayed access to academic hospitals
has been associated with decreased survival in IPF patients
[15]. One mechanism by which these delays may reduce
survival stem from the delay in receiving an accurate diag-
nosis and initiation of ineffective or harmful interventions
[15]. Whether these observations result in differential in-
hospital mortality in patients with IPF remains unknown.
In this investigation, we used the National Inpatient
Sample (NIS) database to assess in-hospital mortality
trends for patients with IPF from 2013 to 2017. We hy-
pothesized that in-hospital IPF mortality would be influ-
enced by hospital setting (academic versus non-academic).
We also assessed whether these trends were influenced by
presence of respiratory failure and use of mechanic venti-
lation. Finally, we assessed whether clinical characteristics




The study was conducted using the NIS database for years
2013–2017. The Agency for Healthcare Research and
Quality developed this data for healthcare cost and
utilization project [16]. All patient data contained in these
database files have been deidentified and are on public rec-
ord; therefore, Institutional Review Board approval for this
study was not required. The NIS assesses the data quality
periodically to ensure its internal validity [17]. It contains
more than 100 clinical data elements from ~ 7 million un-
weighted admissions (weighted to ~ 35 million admissions)
annually, representing 20% of hospital admission in the
United states. It uses ICD-9 codes through September
2015 and ICD-10 codes thereafter.
Study population
We identified records for subjects ≥50 years with any idio-
pathic pulmonary fibrosis (IPF) diagnosis codes (ICD-9,
516.31; ICD-10, J84.112). We excluded any patients who
had concomitant diagnosis codes for connective tissue dis-
eases (CTD), hypersensitivity pneumonitis, other exposure-
related diseases (drugs and radiation) or lung transplant
(Tables E1, E2, E3, E4). We also excluded patients with two
or more idiopathic interstitial pneumonias diagnoses or any
IPF diagnosis along with any code related to non-specific
fibrosis, including those used in prior studies of other
conditions, such as post-inflammatory fibrosis (ICD-9515
and ICD-10 J84.10) (Table E1) [18].
Patient and hospital characteristics
Baseline patients demographics (age, race, and sex) and
relevant comorbidities (smoking, chronic obstructive lung
disease (COPD), asthma, respiratory failure (RF) (acute,
chronic, acute on chronic or non-specified), obstructive sleep
apnea (OSA), gastroesophageal reflux disease (GERD), low
body mass index (BMI < 20), frailty, pneumonia, congestive
heart failure (CHF), obesity, renal failure, liver disease,
diabetes mellitus (DM), hypothyroidism, new pulmonary
embolism (PE) and cancer (Solid and Metastatic)) were
extracted (Table E2, E3, E4). Other inpatient diagnoses and
procedures using ICD-9 and ICD-10 codes (Table E3), Clin-
ical Classifications Software codes (Table E4), and Elixhauser
comorbidities (Table E2) [19–22]. and hospital size and set-
ting for each hospitalization were also extracted.
Outcomes measured
The primary outcome assessed was in-hospital mortality,
defined as death during the hospitalization encounter,
stratified by academic hospital status (academic versus
non-academic). The hospital is identified as an academic
center in the NIS database if it has one or more Accredit-
ation Council for Graduate Medical Education (ACGME)
approved residency programs, is a member of the Council
of Teaching Hospitals (COTH) or has a ratio of full-time
equivalent interns and residents to beds of .25 or higher.
Non-academic hospitals did not meet the above criteria or
located in rural areas. Secondary analyses were performed
in the following subgroups (1) those hospitalized with and
without respiratory failure and (2) those requiring mech-
anical ventilation. A list of the ICD-9 and ICD-10 codes
for the secondary outcome is included in supplementary
materials (Tables E1, E2, E3, E4).
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Statistical analysis
Continuous variables are reported as mean with standard
deviation (SD) and compared using Student’s t-test. Cat-
egorical values are reported as count and percentage com-
pared using the Chi-square test. A Cochran-Armitage test
of trend was used to assess linear trend in mortality. Uni-
variable and multivariable logistic regression was per-
formed to identify independent predictors of in-hospital
mortality. Variables were selected based on previous stud-
ies [23–25]. A Bonferroni correction was applied using all
eighteen terms in the multivariable logistic regression
model resulting in statistical significance being accepted
when p < 0.003 [26]. The area under the curve of the re-
ceiver operator characteristic was calculated to assess risk
explanation. Statistical significance was defined as p < 0.05
unless stated otherwise. Statistical analyses were per-
formed using SPSS (IBM SPSS Statistics for MAC, Ver-
sion 26.0; Armonk, New York: IBM Corp Released 2019)




From 2013 to 2017, 126,230 weighted records with IPF
were identified. Of these, 93,680 hospitalizations met in-
clusion criteria, including 58,450 (62.4%) admitted to an
academic hospital (Fig. 1). We report an incidence of all-
cause hospitalizations among patients with IPF of 44.6
per 100,000 hospitalizations for 2013 and 63.4 per 100,
000 hospitalizations for 2017 which increased by 42.2%
over the five years (Fig. 2). In IPF patients hospitalized
with respiratory failure, the incidence increased by 2
folds as it was 18.6 per 100,000 hospitalizations for 2013
and 39.3 per 100,000 hospitalizations for 2017. While
the incidence for IPF patients with respiratory failure re-
quiring mechanical ventilation increased by 61% from
Fig. 1 STROBE diagram (AIDS: acquired immunodeficiency syndrome; CTD: connective tissue disease; ICD: international classification of diseases;
IPF: idiopathic pulmonary fibrosis; NIS: national inpatient sample)
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was 5.9 per 100,000 hospitalizations for 2013 to 9.5 per
100,000 hospitalizations for 2017 (Fig. 2). Baseline char-
acteristics stratified by the hospital academic status are
presented in (Table 1). Those who are admitted to an
academic institution had significantly more males and
Black patients with a higher proportion of respiratory
failure, obstructive sleep apnea, gastroesophageal reflux
disease, low body mass index, obesity, new pulmonary
embolism, pulmonary circulation disorders, and supple-
mental oxygen therapy use. The same group also had
more patients who underwent bronchoscopy, required
mechanical ventilation, and were admitted for a longer
period. Individuals who are admitted to non-academic
hospitals were significantly older with more White and
Hispanic patients and with a higher proportion of elect-
ive admissions, chronic obstructive pulmonary disease,
pneumonia, and diabetes mellitus.
IPF in-hospital mortality trends
Total hospitalizations, hospitalizations with respiratory
failure and hospitalizations with respiratory failure re-
quiring mechanical ventilation are shown in Fig. 2. Mean
in-hospital mortality for years 2013–2017 was 10.9%,
which showed a non-statistically significant decline over
time (p = 0.12) (Fig. 3 a) (Table E5a). While mortality
for patients admitted to non-academic hospitals was <
10%, mean in-hospital mortality for patients admitted to
academic institution was 11.6%, which declined signifi-
cantly over time (p < 0.001) (Fig. 3 a) (Table E5b). The
in-hospital mortality did not change in those admitted
to non-academic institution (Fig. 3 a) (Table E5b). In-
hospital mortality among patients admitted with respira-
tory failure also decreased among patients admitted to an
academic institution (p < 0.001) and decreased in those ad-
mitted to a non-academic institution (p < 0.001) (Fig. 3 b)
(Table E5b). Among patients requiring mechanical venti-
lation, in-hospital mortality significantly declined in pa-
tients admitted to an academic institution (p < 0.001) but
increased in patients hospitalized in non-academic institu-
tions (P = 0.03) (Fig. 3 c) (Table E5b). While mortality for
patients admitted without respiratory failure was < 5%,
mean in-hospital mortality for patients admitted with re-
spiratory failure was 18.1%, which declined significantly
over time (p < 0.001) (Fig. 4 a) (Table E5c). When asses-
sing patients who required mechanical ventilation, those
without respiratory failure had no change in mortality
(p = 0.1) over time, while those admitted with respiratory
failure showed a significant decline in mortality over time
(p < 0.001) (Fig. 4 b) (Table E5d). When stratifying by age,
mortality was similar across age groups, except IPF
patients in age group (50–59) years old where it declined
significantly (P = 0.001) (Table E5e) (Fig. E1). In addition,
mechanical ventilation therapy declined significantly
in IPF patients with and without respiratory failure
(P < 0.001) (Table E5f) (Fig. E2).
Predictors of in-hospital IPF mortality
In unadjusted logistic regression, predictors of mortality
included admission to an academic hospital, respiratory
failure, receiving mechanical ventilation therapy, bronchos-
copy, frailty, low body mass index, pneumonia, new pul-
monary embolism, and dependence on long-term oxygen
Fig. 2 Temporal trends in IPF related hospitalizations (per 100,000 hospitalizations)
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therapy. Based on Bonferroni correction assessment, elect-
ive admission (OR 1.28, 95% CI 1.16–1.4), admission to an
academic hospital (OR 1.14, 95% CI 1.09–1.2), respiratory
failure (OR 4.77, 95% CI 4.34–5.13), receiving mechanical
ventilation therapy (OR 7.26, 95% CI 6.9–7.64), bronchos-
copy (OR 1.23, 95% CI 1.13–1.33),) low body mass
index (OR 1.51, 95% CI 1.34–1.69), pneumonia (OR
1.38, 95% CI 1.31–1.45), and new pulmonary embolism
(OR 1.83, 95% CI 1.62–2.08) were found to be inde-
pendent predictors of mortality in the multivariable
logistic regression model (Table 2).
Discussion
In this study, we examined in-hospital mortality trends
in patients with IPF from 2013 and 2017, which spanned
the years immediately preceding and after the approval
of anti-fibrotic therapy to treat IPF. We found that while
in-hospital mortality was 10.9%, mortality was higher
among patients admitted to academic hospital (11.6%)
and even significantly higher in those with respiratory
failure (20.5%), and those requiring mechanical ventila-
tion (41.8%) who are admitted to academic centers.
While in-hospital mortality did not significantly change
Table 1 Clinical characteristic between IPF cases admitted to academic vs non-academic hospitals, 2013–2017
Variables IPF hospitalizations in academic
institutions (n = 58,450)
IPF hospitalizations in non-academic
institutions (n = 35,230)
P-Value
Age, mean ± SD 74.5 ± 10.1 75.7 ± 10 < 0.001
Female, n (%) 25,035 (42.8) 15,785 (44.8) < 0.001
Length of stay, mean ± SD 6.6 ± 7 5.7 ± 5 < 0.001
Race < 0.001
White, n (%) 42,330 (76.1) 27,950 (82.8)
Black, n (%) 4785 (8.6) 1715 (5.1)
Hispanic, n (%) 5130 (9.2) 2495 (7.4)
Ever smoker, n (%) 25,760 (44.1) 14,630 (41.5) 0.1
Elective admission, n (%) 6040 (10.4) 3750 (10.7) < 0.001
Respiratory failure, n (%) 31,970 (54.7) 18,585 (52.8) < 0.001
Mechanically ventilated IPF patients, n (%) 9900 (16.9) 5135 (14.6) < 0.001
Bronchoscopy, n (%) 4935 (8.4) 1825 (5.2) < 0.001
Dependence on long-term Oxygen, n (%) 21,320 (36.5) 11,235 (31.9) < 0.001
Co-morbidities
Chronic obstructive lung disease, n (%) 6010 (10.3) 6245 (17.7) < 0.001
Obstructive sleep apnea, n (%) 8530 (14.6) 4035 (11.5) < 0.001
Gastroesophageal reflux disorder, n (%) 19,785 (33.8) 10,435 (29.6) < 0.001
Pneumonia, n (%) 17,440 (29.8) 11,970 (34) < 0.001
Low body mass index, n (%) 2190 (3.7) 985 (2.8) < 0.001
Obesity, n (%) 7265 (12.4) 4015 (11.4) < 0.001
Frailty, n (%) 190 (0.3) 105 (0.3) 0.48
Diabetes mellitus, n (%) 19,430 (33.2) 11,720 (33.3) 0.006
New pulmonary embolism, n (%) 1570 (2.7) 780 (2.2) < 0.001
Asthma, n (%) 4240 (7.3) 2500 (7.1) 0.37
Congestive heart failure, n (%) 15,580 (26.7) 9535 (27.1) 0.17
Pulmonary circulation disease, n (%) 6640 (11.4) 3790 (10.8) 0.005
Chronic renal disease, n (%) 12,215 (20.9) 6595 (18.7) 0.69
Liver disease, n (%) 2150 (3.7) 1045 (3) 0.74
Solid tumor w/o metastasis, n (%) 1755 (3) 1040 (3) 0.66
Metastatic cancer, n (%) 1000 (1.7) 590 (1.7) 0.68
Hypothyroidism, n (%) 11,460 (19.6) 7020 (19.9) 0.23
Elixhauser sum of conditions
Mean ± SD 4 ± 2 4 ± 2 0.22
Alqalyoobi et al. BMC Pulmonary Medicine          (2020) 20:289 Page 5 of 11
over time for all-comers, mortality did significantly de-
crease in patients admitted to academic hospitals, including
those with respiratory failure and those requiring mechan-
ical ventilation. We reported no significant change in all-
cause mortality in patients admitted to a non-academic
institution. While respiratory failure associated mortality
decreased significantly in IPF patients admitted to non-
academic centers, mechanical ventilation-associated mor-
tality increased significantly in this group. Subgroup
analysis showed that mortality did significantly decrease in
patients admitted with respiratory failure and in those re-
quiring mechanical ventilation. These observations might
suggest that the early referral to academic centers may re-
duce IPF mortality.
Our data demonstrate increasing all-cause hospitaliza-
tions for patients with IPF from 2013 to 2017, which may
reflect previously reported increasing incidence and preva-
lence of IPF in the US [27, 28]. Despite this increase in
Fig. 3 a Temporal trend in all-cause mortality among hospitalized patients with IPF among all-comers and after stratification by hospital setting
(IPF: idiopathic pulmonary fibrosis). b Temporal trend in mortality in IPF patients with respiratory failure stratified by hospital academic status. c
Temporal trends in mechanical ventilation associated mortality stratified by academic status of the hospital
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hospitalizations, our data suggest a relatively static in-
hospital mortality for patients admitted during this time-
frame. These findings are supported by others using the
NIS dataset, who reported similar all-cause mortality in
patients with IPF admitted to the hospital 2006 to 2012
[29] and others using a similar dataset, who reported IPF
mortality during index admission from 2011 and 2014 to
be 10.3% [30]. These findings stand in contrast to those
published using the online CDC national death certificate
database, which showed IPF-related mortality to be
increasing over this timeframe [31, 32]. Besides, others re-
ported decline in IPF all-cause mortality and hospitaliza-
tions using NIS dataset [33]. With different case finding
methodologies employed by each study, these observa-
tions highlight the difficulties with capturing accurate IPF
data using claims databases.
During the study period, when IPF hospitalizations were
stratified by hospital academic status, we found a significant
decline in all-cause mortality, respiratory failure associated
mortality and mechanical ventilation associated mortality in
IPF patients admitted to teaching hospitals. Interestingly,
we found a significant increase in mechanical ventilation
associated mortality in IPF patients hospitalized in a non-
academic institution. No significant changes in all-cause
mortality in IPF patient admitted to a non-academic
hospital while respiratory associated mortality decreased
significantly in the same group. The reasons underpinning
these observations remain unclear but may suggest a stron-
ger adherence to 2015 IPF treatment guidelines at academic
centers [34]. Besides, others have shown that significant
disagreement exists in the diagnosis of ILD between
community-based physicians and academic physicians [14].
We also hypothesize that formal multidisciplinary discus-
sion for IPF diagnosis would be conducted in academic
centers and unlikely to be performed in non-academic in-
stitutions [35]. Early access to lung transplant service and
Fig. 4 a Temporal trends in mortality stratified by the presence of respiratory failure. b Temporal trends in mechanical ventilation associated
mortality stratified by presence of respiratory failure
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anti-fibrotic therapy might explain this observation as well.
Others have shown that early referral of IPF patients to
tertiary care centers is associated with reduced mortality,
supporting an added benefit provided at these centers [15].
We also found that admissions to the academic centers
were associated with higher mortality risk, which is similar
to previous studies [36]. This might reflect more advanced
diseases in IPF patients referred to the academic centers as
they included patients referred for lung transplant evalu-
ation and other advanced therapeutics. We also speculate
that academic centers receive sicker IPF patients as admis-
sion to academic centers is described as an independent
risk factor for receiving mechanical ventilation therapy [36].
However, our assumption is limited by our data type and
documentation bias.
We observed a significant decline in respiratory failure-
associated mortality over the years assessed. Additionally,
despite the plateau in mechanical ventilation associated
mortality in the whole cohort, mechanical ventilation ther-
apy and mechanical ventilation associated mortality in the
respiratory failure group declined significantly. The mor-
tality rate in IPF patients with respiratory failure receiving
mechanical ventilation therapy has been reported to range
from 50 to 90% [2, 29, 36]. Others reported mortality of
55.7% in intubated IPF patients between 2009 and 2011
using a different case definition for IPF codes (ICD9,
516.3). [36]Another study showed declining mortality be-
tween 2006 and 2013 from 58.4 to 49.3% using the same
database, but different case definition [29]. In our cohort,
the decline in the respiratory failure associated mortality,
mechanical ventilated associated mortality and mechanical
ventilation therapy is likely multifactorial and might reflect
evolving and increased adherence to evidence-based
pharmacological and non-pharmacological management
strategies [34].
The influence of comorbid conditions and interventions
on IPF mortality has been increasingly studied over the last
decade [23]. Our study supports the findings of others
who have shown age, sex [30, 37–39], race and smoking
history [37, 38, 40] to confer differential mortality risk. Re-
spiratory failure and need for mechanical ventilation ther-
apy were the strongest predictors of in-hospital mortality,
which supports prior findings [7, 30]. It is unclear why
elective admission has been associated with increased
Table 2 Conditions and interventions predicting in-hospital mortality in patients with IPF patients
Risk factors Unadjusted Adjusted Model*
OR p-value 95%CI OR p-value** 95%CI
Age 0.995 < 0.001 (0.993–0.997) 1.007 < 0.001 (1.004–1.009)
Female 0.72 < 0.001 (0.7–0.76) 0.77 < 0.001 (0.73–0.81)
Race***:
Black 0.83 < 0.001 (0.76–0.91) 0.69 < 0.001 (0.62–0.76)
Hispanic 0.9 0.008 (0.83–0.97) 0.67 < 0.001 (0.62–0.74)
Ever Smoker 0.83 < 0.001 (0.8–0.86) 0.79 < 0.001 (0.75–0.83)
Elective admission 0.63 < 0.001 (0.58–0.68) 1.28 < 0.001 (1.16–1.4)
Academic hospital 1.21 < 0.001 (1.16–1.27) 1.14 < 0.001 (1.09–1.2)
Any respiratory failure 8.67 < 0.001 (8.13–9.25) 4.77 < 0.001 (4.34–5.13)
Mechanical ventilation therapy 11.36 < 0.001 (10.86–11.88) 7.26 < 0.001 (6.9–7.64)
Bronchoscopy 2.25 < 0.001 (2.11–2.39) 1.23 < 0.001 (1.13–1.33)
Gastroesophageal reflux disorder 0.82 < 0.001 (0.78–0.86) 0.84 < 0.001 (0.8–0.89)
Obstructive sleep apnea 0.78 < 0.001 (0.74–0.84) 0.62 < 0.001 (0.58–0.67)
Diabetes mellitus 0.94 0.008 (0.9–0.99) 0.91 0.001 (0.87–0.96)
Frailty 1.67 0.001 (1.23–2.27) 1.48 0.03 (1.04–2.1)
Low body mass index 1.65 < 0.001 (1.5–1.82) 1.51 < 0.001 (1.34–1.69)
Obesity 0.81 < 0.001 (0.76–0.87) 0.77 < 0.001 (0.71–0.84)
Pneumonia 2.31 < 0.001 (2.22–2.41) 1.38 < 0.001 (1.31–1.45)
New pulmonary embolism 2.18 < 0.001 (1.97–2.42) 1.83 < 0.001 (1.62–2.08)
Dependence on long-term Oxygen 1.23 < 0.001 (1.18–1.28) 0.91 < 0.001 (0.87–0.96)
*Adjusted for all variables mentioned in this table
** Statistically significant P-value cutoff after Bonferroni correction is (p < 0.003)
*** Compared to white
The logistic regression model was statistically significant, χ2 = 14,153.7, p < 0.001. The model explained 29.7% (R2) of the variance in mortality and correctly
classified 89.4% of cases. Sensitivity was 16.1%, specificity was 98.3%, positive predictive value was 53% and negative predictive value was 90.7%. The area under
the ROC curve was 0.835 (95% CI, 0.831 to 0.839), which is an excellent level of discrimination (Figs. E3)
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mortality. One theory would be that elective admissions
might be related to referrals from non-academic hospitals
or urgent admissions from the outpatient clinic. In our as-
sessment of comorbid conditions, our findings supported
the work of other showing mortality risk to be increased in
patients with pneumonia, [36, 41] low body mass index,
[42] and thromboembolic disease, [43]. We found that
those with concurrent obesity, GERD, diabetes and sleep
apnea had lower mortality risk, which adds to mixed re-
sults with these conditions [24, 25, 44–46]. Finally, long
term oxygen therapy was associated with decreased in-
hospital mortality in our analysis. It is unclear if this is a
true effect or this result is confounded by the presence of
other diseases in which oxygen use is associated with im-
proved survival. Further studies need to evaluate the im-
pact of long-term oxygen use on IPF patients’ survival.
This study has several limitations. First, we used an ad-
ministrative database, in which coding and documentation
errors are inherent limitations. In attempts to mitigate the
potential errors, multiple internal quality control measures
are conducted to validate the NIS [17]. In addition, ICD-
coding for IPF patients is challenging, given the complexity
of the IPF diagnosis process, and might be another source
of error. Therefore, we adopted a conservative approach
which may result in missed cases and lower sensitivity at
the expense of increased specificity. We included only pa-
tients with IPF specific codes (ICD-9, 516.31; ICD-10,
J84.112), and we did not include less precise codes (ICD9,
516.3 or 515; ICD10, J84.1 or J84.9) used in previous studies
[29–31, 36].. Vu et al. [18] showed in a USA population-
based study that only 4% of patients with IPF ICD9 code
515 had definite or probable IPF by 2018 Fleischner criteria.
A Finnish study showed that 20–30% of patients with
ICD10 codes J84.1 or J84.9 met IPF criteria [47]. We also
excluded any patients who had a concomitant diagnosis of
environmental exposure or CTD [48]. Second, our study is
a retrospective observational study based on discharge data,
and it is liable to selection bias and can only assess associ-
ation and not assess causation. Finally, the population stud-
ied in this period is heterogenous as it includes patients
treated with and without antifibrotic therapy. We were not
able to retrieve antifibrotic treatment data for our analysis,
therefore our results may or may not reflect the impact of
the 2014 approval of anti-fibrotic therapy for the treatment
of IPF. However, our data do potentially support the work
of others, who have shown antifibrotic therapy to be associ-
ated with decreased mortality, respiratory hospitalization
and AE-IPF [6, 10, 49].
Conclusion
This observational analysis from a nationally representa-
tive inpatient sample from 2013 to 2017 showed a decline
in all-cause mortality, respiratory associated mortality and
mechanical ventilation associated mortality in IPF patients
admitted to academic hospitals, while mechanical ventila-
tion associated mortality increased in those admitted to
non-academic hospitals. We also found that respiratory
failure associated mortality and mechanical ventilation as-
sociated mortality decreased in IPF patients over the same
period. Our findings may underscore the importance of
promoting timely diagnosis, early referral to an academic
institution and adherence to international treatment
guidelines. It is not clear why despite the significant de-
cline in overall mortality, admission to the academic cen-
ters remain an independent predictor of mortality. Further
research is needed to elucidate the factors driving these
findings.
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